The validity of anti-PRMT5 antibodies rather than anti-PRMT1, HK-1 or CD5L antibodies with higher specificity and sensitivity for SSc leads to the next in-depth investigation for anti-PRMT5 in SSc. This evidence concerns the gene PRMT1 and systemic sclerosis.